Mubadala and G42 to acquire Diaverum from Bridgepoint for $2bn.

Mubadala, an investment company, and G42, an artificial intelligence firm, agreed to acquire Diaverum, a health care provider, from Bridgepoint, a private equity firm, for $2bn. “Diaverum is an exceptional company providing vital treatments that enable patients suffering from chronic kidney disease to live fulfilling lives. Its pioneering digital care offering fully aligns with M42’s focus on leveraging advanced technological solutions to deliver precise, personalized patient care,” Hasan Jasem Al Nowais, Mubadala Health Chief Executive Officer.